Germany's Curevac was supposed to be a big player in COVID vaccinations. But now important tests have disappointed. With an efficacy rate of just 47 percent, a much hyped vaccine is not useful. The EU had already ordered 400 million doses.
For more news go to: www.dw.com/en/
Follow DW on social media:
Für Videos in deutscher Sprache besuchen Sie: www.youtube.com/dwdeutsch
#CureVac #Vaccine #Coronavirus